Candidate biomarkers for cervical cancer treatment: Potential for clinical practice (Review)
Miho Iida(Keio University), Daisuke Aoki(International University of Health and Welfare), Kyoko Tanaka(Keio University), Iori Kisu(Fujita Health University), Yuya Nogami(Keio University), Masataka Adachi(Keio University), Megumi Yanokura(Keio University), Kenta Masuda(Keio University), Takashi Iwata(Keio University), Kiyoko Umene(Keio University), K. Nakamura(Teikyo Heisei University), Kouji Banno(Keio University)
Cited by 40
Related Papers
Pathological Steps of Cancer-Related Lymphedema: Histological Changes in the Collecting Lymphatic Vessels after Lymphadenectomy
|PLoS ONE|2012|331
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|214
MicroRNA in Cervical Cancer: OncomiRs and Tumor Suppressor miRs in Diagnosis and Treatment
|The Scientific World JOURNAL|2014|143
Cross‐sectional analysis of germline <i>BRCA</i>1 and <i>BRCA</i>2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer
|Cancer Science|2008|105
Registry of the International Society of Uterus Transplantation: First Report
|Transplantation|2022|100